BAYER AG
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause
- Conditions
- Vasomotor Symptoms Associated With MenopauseHot Flashes
- Interventions
- Drug: Elinzanetant (BAY3427080)Drug: Placebo
- First Posted Date
- 2021-09-13
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Bayer
- Target Recruit Count
- 396
- Registration Number
- NCT05042362
- Locations
- 🇺🇸
Soapstone Center for Clinical Research, Decatur, Georgia, United States
🇺🇸HWC Women's Research Center | Englewood, OH, Englewood, Ohio, United States
🇺🇸Alliance for Multispecialty Research, LLC - Fort Meyers, Fort Myers, Florida, United States
A Study to Learn How Well a Monitoring System Called Continuous Glucose Monitoring (CGM) Which Measures Glucose on an Ongoing Basis Works and How Safe it is in Chinese Patients in Usual Practice
- Conditions
- Diabetes MellitusContinuous Glucose Monitoring
- Interventions
- Device: CGM SystemProcedure: Standard Venous Blood Glucose Test
- First Posted Date
- 2021-09-09
- Last Posted Date
- 2023-03-09
- Lead Sponsor
- Bayer
- Target Recruit Count
- 76
- Registration Number
- NCT05038761
- Locations
- 🇨🇳
Many locations, Multiple Locations, Many Locations, China
🇨🇳Many Locations, Multiple Locations, China
A Study to Observe Treatment Patterns in Patients in Colombia Who Have Heart Failure
- Conditions
- Heart Failure
- Interventions
- Drug: HF medication
- First Posted Date
- 2021-09-08
- Last Posted Date
- 2022-12-15
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1000
- Registration Number
- NCT05036967
- Locations
- 🇨🇴
Many Locations, Multiple Locations, Colombia
Prophylaxis Regimen for Hemophilia A Patients
- Conditions
- Hemophilia AProphylaxis of Bleeding
- Interventions
- Biological: Damoctocog alfa-pegol is a recombinant B-domain deleted human coagulation FVIII variant site specifically conjugated with a 60 kDa, branched (30 kDa each) polyethylene glycol (PEG).
- First Posted Date
- 2021-09-05
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 21
- Registration Number
- NCT05036278
- Locations
- 🇺🇸
Dr. Akshat Jain - Loma Linda University Medical Center, Loma Linda, California, United States
🇺🇸Orthopaedic Institute for Children, Los Angeles, California, United States
🇺🇸Loma Linda Children's Hospital, San Bernardino, California, United States
A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 52 Weeks in Women Who Have Been Through the Menopause
- Conditions
- Vasomotor Symptoms Associated With MenopauseHot Flashes
- Interventions
- Drug: PlaceboDrug: Elinzanetant (BAY3427080)
- First Posted Date
- 2021-09-01
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Bayer
- Target Recruit Count
- 628
- Registration Number
- NCT05030584
- Locations
- 🇺🇸
Mesa Obstetricians and Gynecologists, Mesa, Arizona, United States
🇺🇸David I Lubetkin, MD, LLC, Boca Raton, Florida, United States
🇺🇸HWC Women's Research Center, Englewood, Ohio, United States
A Study to Learn What Happens to Elinzanetant in the Body When Taken With or Without Carbamazepine, and How Safe it is in Healthy Men and Women Aged 18 to 60 Years.
- Conditions
- Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men
- Interventions
- First Posted Date
- 2021-08-31
- Last Posted Date
- 2022-02-25
- Lead Sponsor
- Bayer
- Target Recruit Count
- 16
- Registration Number
- NCT05028608
- Locations
- 🇩🇪
CRS Clinical-Research-Services Mannheim GmbH, Mannheim, Baden-Württemberg, Germany
A Clinical Trial to Compare Safety and Effectiveness for Relieving Tenderness of 10% Naproxen Gel vs. a 2.32% Diclofenac Diethylamine Gel in the Treatment of Strains and Bruises of the Legs.
- Conditions
- Soft Tissue Injury
- Interventions
- First Posted Date
- 2021-08-30
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Bayer
- Target Recruit Count
- 76
- Registration Number
- NCT05026320
- Locations
- 🇩🇪
Deutsche Sporthochschule Köln (DSHS), Köln, Nordrhein-Westfalen, Germany
A Study to Learn Whether There Are Differences in the Kidney's Ability to Work Properly in Korean Patients With Non-valvular Atrial Fibrillation (Irregular and Often Rapid Heartbeat Not Caused by a Heart Valve Problem) Treated With Rivaroxaban as Compared to Those Treated With Warfarin
- Conditions
- Non-valvular Atrial Fibrillation (NVAF)
- Interventions
- First Posted Date
- 2021-08-26
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- Bayer
- Target Recruit Count
- 45000
- Registration Number
- NCT05022758
- Locations
- 🇰🇷
Many locations, Multiple Locations, Korea, Republic of
An add-on Study to the FIGARO-DKD Study Called FIGARO-BM to Learn About the Link Between Biomarkers (Substances in the Blood Used as Indicators of Biological Processes, Disease Processes or Responses to Medication) and Finerenone in FIGARO-DKD Participants
- Conditions
- Chronic Kidney DiseaseType 2 Diabetes Mellitus
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-08-19
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- Bayer
- Target Recruit Count
- 951
- Registration Number
- NCT05013008
- Locations
- 🇨🇳
Taipei Medical University Hospital, Taipei, Taiwan
🇺🇸Florida Kidney Physicians - Fort Lauderdale, Fort Lauderdale, Florida, United States
🇺🇸Indago Research & Health Center, Inc., Hialeah, Florida, United States
A Study to Learn More About Chronic Kidney Disease (CKD) in Patients With Type 2 Diabetes Mellitus (T2DM)
- Conditions
- Type 2 Diabetes MellitusChronic Kidney Disease
- Interventions
- Other: No intervention
- First Posted Date
- 2021-08-13
- Last Posted Date
- 2023-02-14
- Lead Sponsor
- Bayer
- Target Recruit Count
- 336376
- Registration Number
- NCT05004428
- Locations
- 🇨🇦
Many Locations, Multiple Locations, Canada